On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.
about
Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy?Vitamin D prohormone in the treatment of secondary hyperparathyroidism in patients with chronic kidney disease.Bone and soft tissue changes with oral phosphate supplementsChronic kidney disease: mineral and bone disorder in children.The effects in the rat of varying intakes of dietary calcium, phosphorus, and hydrogen ion on hyperparathyroidism due to chronic renal failureSuppression of secondary hyperparathyroidism in children with chronic renal failure by high dose phosphate binders: calcium carbonate versus aluminium hydroxide.Etiology of hyperparathyroidism and bone disease during chronic hemodialysis. 3. Evaluation of parathyroid suppressibilityHypocalcemia may not be essential for the development of secondary hyperparathyroidism in chronic renal failure.Reduction of dietary phosphorus absorption by phosphorus binders. A theoretical, in vitro, and in vivo study.1,25-dihydroxycholecalciferol in renal osteodystrophy. Epiphysiolysis--anticonvulsant therapyDo aluminium-based phosphate binders continue to have a role in contemporary nephrology practice?Metabolism in immunoreactive parathyroid hormone in the dog. The role of the kidney and the effects of chronic renal disease.Influence of dietary phosphorus on renal phosphate reabsorption in the parathyroidectomized ratEffect of dietary phosphorus on circulating concentrations of 1,25-dihydroxyvitamin D and immunoreactive parathyroid hormone in children with moderate renal insufficiency.The case for routine parathyroid hormone monitoring.Hyperparathyroid bone disease in chronic renal failure.Correlates of parathyroid hormone concentration in hemodialysis patients.Phosphate Toxicity in CKD: The Killer among UsReversal of secondary hyperparathyroidism by cimetidine in chronically uremic dogs.Altered mineral metabolism in glucocorticoid-induced osteopenia. Effect of 25-hydroxyvitamin D administration.Phosphate control and 25-hydroxycholecalciferol administration in preventing experimental renal osteodystrophy in the dog.Inhibition of parathyroid hormone secretion by 25-hydroxycholecalciferol and 24,25-dihydroxycholecalciferol in the dog.Neurodiagnostic abnormalities in patients with acute renal failureEarly chronic kidney disease-mineral bone disorder stimulates vascular calcification.Phosphorus restriction prevents parathyroid gland growth. High phosphorus directly stimulates PTH secretion in vitro.The regulation of parathyroid hormone secretion and synthesis.The intact nephron hypothesis: the concept and its implications for phosphate management in CKD-related mineral and bone disorder.FGF23 and PTH--double agents at the heart of CKD.Renal pathophysiology: lessons learned from the canine remnant kidney model.The role of phosphorus in the pathophysiology of chronic kidney disease.Hyperparathyroidism in chronic kidney disease patients: an update on current pharmacotherapy.Calcitriol, calcidiol, parathyroid hormone, and fibroblast growth factor-23 interactions in chronic kidney disease.FGF23: a mature renal and cardiovascular risk factor?FGF-23 and secondary hyperparathyroidism in chronic kidney disease.Optimal use of phosphate binders in chronic kidney disease.Oral phosphate binders: phosphate binding capacity of iron (III) hydroxide complexes containing saccharides and their effect on the urinary excretion of calcium and phosphate in rats.Control of phosphate balance by the kidney and intestine.Phosphate Additive Avoidance in Chronic Kidney Disease.Hormonal derangements in uremia.Pathophysiology of parathyroid hyperplasia in chronic kidney disease: preclinical and clinical basis for parathyroid intervention.
P2860
Q33684149-CF914A62-97C4-4E1F-8634-E7DD66E63072Q33703957-19FF052B-6C3C-4FBC-86C3-8DDEA75172DAQ34075170-0F797B7A-7BA2-4CEA-8113-5A3E684F27A1Q34402661-43C458F5-5657-409A-B6CC-00153B34A3A9Q34460158-66842A57-567B-411D-AD42-0E76A2BA1F97Q34488869-C6DAE917-CCC0-46EA-B445-618158CFCAC9Q34497878-FCCCAB47-DBB8-4E11-B83C-EB2FEC871A37Q34543837-37B442D9-4888-4827-97E9-229DA7904A03Q34563650-273C29C4-034F-4217-9B45-66D441EA0C51Q34985705-6E96C3A4-72F8-434A-9C17-6F04B438B1D3Q35021546-E2C50768-182D-4A00-8FDC-CEEA127F5B50Q35194038-9ED25475-4250-4A9E-8998-768DE3C7D138Q35199506-D0C591B7-44AB-4896-B47F-8CDFFCB7AFF4Q35208799-66D728B3-BF59-4DC2-B2E1-6276FB07E2B6Q36583342-37239843-F484-4BEA-BBB1-49E3B1E2490DQ36749771-B790C86B-952C-4D9C-B04B-43C2A8B1E660Q36936601-C52513E2-DB64-46D5-809B-13814252CB8EQ36965142-78402104-0693-49F2-A92D-B3D3291D77ADQ37000238-BFC0424C-CBCB-488A-8A5D-921369B584EEQ37041053-98B7BCD0-3F68-4098-9E73-22BD43DB5542Q37045927-85ADBCC5-7731-4242-866A-A21A0A1CF233Q37053921-BA000422-27FF-45C7-94A9-DD2236355D69Q37054042-4C8FEF06-0343-47A2-A8DB-691E8C97045DQ37333243-F8CA1BF2-60DA-40F2-8CEC-BBA965616A6CQ37355688-8C758C11-BE6B-4C40-8CE9-FDBCCDD3644BQ37821623-4DBB03EB-6603-426F-96B9-A167784D4987Q37846524-7BE88E31-357E-406C-8FC3-EFE356A58C77Q37996937-A7FB1429-7232-4401-9C56-654197F5AEF0Q38086888-F7310942-2064-4355-BA70-8C7F3788DF04Q38086910-8C8F523A-A35D-4B91-9590-CDDDC94123BDQ38092144-7A4EC47B-0203-46B2-9644-DC11DFB47318Q38097111-DB25ACAD-6252-437D-B756-0AD05250E810Q38111898-25308A4C-5D19-4CD4-BCE0-83662B5DDCD0Q38123396-CCDA985A-B39A-4798-B665-F335F7A4E0B2Q38161580-37B5E657-1E04-48CA-9636-8EC58C6E3F32Q38319620-785ABBAA-6469-4D62-A5F8-B566E5D1E65DQ39024187-5645A4E8-5CB3-43E6-9FC3-65ED57808808Q39355201-5C34EED4-D1C2-4A69-87E4-A125C7FFD2EFQ40283255-39D5BE2C-68AC-4726-81E4-6252DB8ADB71Q40318301-6AFFFB26-1E51-4CB2-90AC-CDD13E7457B4
P2860
On the pathogenesis of hyperparathyroidism in chronic experimental renal insufficiency in the dog.
description
1971 nî lūn-bûn
@nan
1971 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1971 թվականի մարտին հրատարակված գիտական հոդված
@hy
1971年の論文
@ja
1971年論文
@yue
1971年論文
@zh-hant
1971年論文
@zh-hk
1971年論文
@zh-mo
1971年論文
@zh-tw
1971年论文
@wuu
name
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@ast
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@en
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@nl
type
label
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@ast
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@en
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@nl
prefLabel
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@ast
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@en
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@nl
P2093
P2860
P356
P1476
On the pathogenesis of hyperpa ...... enal insufficiency in the dog.
@en
P2093
Bricker NS
Canterbury JM
Pennell JP
Slatopolsky E
Taggart DD
P2860
P304
P356
10.1172/JCI106517
P407
P577
1971-03-01T00:00:00Z